Larkin JM - Search Results

1

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z. Swanton C, et al. Among authors: larkin jm. Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174. Genome Med. 2010. PMID: 20701793 Free PMC article.

2

The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.

Larkin JM, Gore ME. Larkin JM, et al. Clin Oncol (R Coll Radiol). 2005 Aug;17(5):319-21. doi: 10.1016/j.clon.2005.03.007. Clin Oncol (R Coll Radiol). 2005. PMID: 16097560 No abstract available.

3

Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.

Larkin JM, Norsworthy PJ, A'Hern RP, Eisen TG, Gore ME, Porter CD. Larkin JM, et al. Melanoma Res. 2006 Apr;16(2):157-63. doi: 10.1097/01.cmr.0000200490.62723.b0. Melanoma Res. 2006. PMID: 16567971

4

Drug insight: advances in renal cell carcinoma and the role of targeted therapies.

Larkin JM, Chowdhury S, Gore ME. Larkin JM, et al. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. doi: 10.1038/ncponc0901. Nat Clin Pract Oncol. 2007. PMID: 17657252 Review.

5

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

Chowdhury S, Larkin JM, Gore ME. Chowdhury S, et al. Among authors: larkin jm. Eur J Cancer. 2008 Oct;44(15):2152-61. doi: 10.1016/j.ejca.2008.06.028. Epub 2008 Sep 29. Eur J Cancer. 2008. PMID: 18829302 Review.

6

Malignant melanoma (metastatic).

Larkin J, Gore M. Larkin J, et al. BMJ Clin Evid. 2008 Aug 22;2008:1718. BMJ Clin Evid. 2008. PMID: 19445806 Free PMC article. Review.

7

Health policy: The UK 'postcode lottery' in renal cell carcinoma.

Larkin J, Gore M. Larkin J, et al. Nat Rev Urol. 2009 Dec;6(12):636-8. doi: 10.1038/nrurol.2009.228. Nat Rev Urol. 2009. PMID: 19956190 No abstract available.

8

Is advanced renal cell carcinoma becoming a chronic disease?

Larkin J, Gore M. Larkin J, et al. Lancet. 2010 Aug 21;376(9741):574-5. doi: 10.1016/S0140-6736(10)60816-1. Lancet. 2010. PMID: 20728740 No abstract available.

9

Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.

Larkin JM, Pyle LM, Gore ME. Larkin JM, et al. Oncologist. 2010;15(11):1135-46. doi: 10.1634/theoncologist.2010-0078. Epub 2010 Nov 4. Oncologist. 2010. PMID: 21051659 Free PMC article.

10

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.

Gore ME, Larkin JM. Gore ME, et al. Among authors: larkin jm. Br J Cancer. 2011 Feb 1;104(3):399-406. doi: 10.1038/sj.bjc.6606084. Br J Cancer. 2011. PMID: 21285971 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters